The DOI matches its Crossref record; 9 of the 10 references it cites were found in a registry or an index.
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Open accessAbstract
Objective To report 5-year results from a previously reported trial evaluating intravitreal 0.5 mg ranibizumab with prompt versus deferred (for ≥24 weeks) focal/grid laser treatment for diabetic macular edema (DME).Design Multicenter, randomized clinical trial.Participants Among participants from the trial with 3 years of follow-up who subsequently consented to a 2-year extension and survived through 5 years, 124 (97%) and 111 (92%) completed the 5-year visit in the prompt and deferred groups, respectively.Methods Random assignment to ranibizumab every 4 weeks until no longer improving (with resumption if worsening) and prompt or deferred (≥24 weeks) focal/grid laser treatment.Main outcome measures Best-corrected visual acuity at the 5-year visit.Results The mean change in visual acuity letter score from baseline to the 5-year visit was +7.2 letters in the prompt laser group compared with +9.8 letters in the deferred laser group (mean difference, -2.6 letters; 95% confidence interval, -5.5 to +0.4 letters; P = 0.09). At the 5-year visit in the prompt versus deferred laser groups, there was vision loss of ≥10 letters in 9% versus 8%, an improvement of ≥10 letters in 46% versus 58%, and an improvement of ≥15 letters in 27% versus 38% of participants, respectively. From baseline to 5 years, 56% of participants in the deferred group did not receive laser. The median number of injections was 13 versus 17 in the prompt and deferral groups, including 54% and 45% receiving no injections during year 4 and 62% and 52% receiving no injections during year 5, respectively.Conclusions Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment. Although more than half of eyes in which laser treatment is deferred may avoid laser for at least 5 years, such eyes may require more injections to achieve these results when following this protocol. Most eyes treated with ranibizumab and either prompt or deferred laser maintain vision gains obtained by the first year through 5 years with little additional treatment after 3 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“where the majority of patients do not require treatment beyond 3 years.”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [35]
In the citing paper
“In Diabetic Retinopathy Clinical Research Network Protocol I clinical trial, a mean of 8 or 9 injections were given in Year 1, decreasing to 2 or 3 in Year 2, to 1 or 2 in Year 3, and to 0 or 1 in Year 4, depending on treatment assignment.35”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Elman, M. J., Aiello, L. P., Beck, R. W., Bressler, N. M., Bressler, S. B., Edwards, A. R., Ferris, F. L., Friedman, S. M., Glassman, A. R., Miller, K. M., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.031 · Cited by 1,431
Self-citationMitchell, P., Bandello, F. M., Schmidt-Erfurth, U. M., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,344
Elman, M. J., Bressler, N. M., Qin, H., Beck, R. W., Ferris, F. L., Friedman, S. M., Glassman, A. R., Scott, I. U., Stockdale, C. R., & Sun, J. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.033 · Cited by 572
Self-citationIntravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment
Elman, M. J., Qin, H., Aiello, L. P., Beck, R. W., Bressler, N. M., Ferris, F. L., Glassman, A. R., Maturi, R. K., & Melia, M. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.08.022 · Cited by 322
Self-citationMixed models for longitudinal data
Cecílio‐Fernandes, D., Tio, R. A., & Jaarsma, D. A. D. C. (2016) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 118
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citationInference for the Marginal Model
(2009) · Springer series in statistics · doi:10.1007/978-1-4419-0300-6_6 · Cited by 6
Cited by
Sorted by citations
Items 501–560 of 560
Addou-Regnard, M. (2015) · HAL
Ophthalmic Issues in Chronic Kidney Disease
Kummer, A., Dalal, M. D., Chew, E. Y., & Weber, M. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00020-2
Larson, J. C., & Mititelu, M. (2016) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2016.03.022
Ilieva, E., Petkova, I., & Telbizova-Radovanova, K. (2014)
Díaz-Rodríguez, R., González, R. A., Dolz‐Marco, R., & Gallego‐Pinazo, R. (2017) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2016.11.007
Díaz-Rodríguez, R., González, R. A., Dolz‐Marco, R., & Gallego‐Pinazo, R. (2017) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2017.03.001
Corticosteroids: Targeting Multiple Cytokines and Chemokines
Stewart, M. W. (2017) · Springer eBooks · doi:10.1007/978-981-10-3509-8_5
Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes
Introini, U., & Casalino, G. (2017) · Developments in ophthalmology · doi:10.1159/000460220
Structural and Vascular Changes Following Laser for Diabetic Macular Edema
Leontieva, E. (2016) · TSpace (University of Toronto)
Anti-angiogenesis Therapy in Diabetic Retinopathy
Stewart, M. W. (2017) · Springer eBooks · doi:10.1007/978-3-319-61115-0_13
Curing diabetic retinopathy: Is a strategy emerging?
Stewart, M. W. (2015) · World Journal of Ophthalmology · doi:10.5318/wjo.v5.i4.142
Diabetic macular edema: Efficacy and safety of anti-vascular endothelial growth factor therapy
Güler, E. (2015) · World Journal of Ophthalmology · doi:10.5318/wjo.v5.i3.133
Retinopathie erfordert Teamarbeit
Bertram, B., Lemmen, K. D., Agostini, H. T., Ziemssen, F., Hammes, H., & Landgraf, R. (2018) · Info Diabetologie · doi:10.1007/s15034-018-1236-1
Rezidivierendes diabetisches Makulaödem: Was tun?
Gonçalves, R., Teixeira, C., & Coelho, P. (2018) · Kompass Ophthalmologie · doi:10.1159/000489535
Diabetic Retinopathy and Its Management
Wykoff, C. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-04019-2_5
Diyabetik Makula Ödeminde Bevacizumab Tedavisi: Gerçek Bir Yaşam Çalışması
Göker, Y. Ş., Tekin, K., Kızıltoprak, H., Atılgan, C. Ü., & Kösekahya, P. (2019) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.539984
Overview of Therapies for Diabetic Macular Edema
Gabriela, Y. C. M. (2019) · Interventions in Obesity & Diabetes · doi:10.31031/iod.2019.03.000552
Diabetic Macular Edema: Is Your Patient Going Blind?
Weber, M. L. (2015) · Europe PMC (PubMed Central)
Hamdi, K. (2020) · Scientific Research Journal · doi:10.31364/scirj/v8.i4.2020.p0420758
Modern principles of the diabetic macular edema management
Nk, M., & Stoliarenko, G. E. (2020) · Ophthalmology Reports · doi:10.17816/ov33036
Sugimoto, M., Chujo, S., Sasaki, T., Ichio, A., Miyata, R., Matsubara, H., & Kondo, M. (2019) · doi:10.21203/rs.2.16775/v1
Danni, R. (2021) · Työväentutkimus Vuosikirja
Diagnosis and Management of Ophthalmic Complications of Diabetes
Barkmeier, A. J., & Astafurov, K. V. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch21
Scanlon, P. H. (2022) · doi:10.1093/med/9780198870197.003.0276
Sugimoto, M., Chujo, S., Sasaki, T., Ichio, A., Miyata, R., Matsubara, H., & Kondo, M. (2020) · doi:10.21203/rs.2.21161/v1
Frank, R. N., & Glybina, I. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.01430-9
Zaky, M., Mohammed, M., & Hodieb, A. E. (2022) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.21608/aimj.2022.112254.1739
Knezović, K., Sesar, A., Sesar, A. P., Sesar, I., Ćavar, I., & Merdžo, I. (2022) · Annals of biomedical and clinical research · doi:10.47960/2744-2470.2022.1.1.28
Ashraf, M., Gilbert, M. J., Rageh, A., Souka, A., & Sun, J. K. (2021) · Egyptian Retina Journal · doi:10.4103/erj.erj_4_22
Long term outcomes following anti-VEGF therapy for diabetic macular edema
Maatouk, C. M., Sastry, R., & Singh, R. P. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2131539
Treatment Outcomes of Suprachoroidal Triamcinolone Injection in Refractory Diabetic Macular Edema
Haider, M. A., Usman, N., Buksh, H. M., & Jabran, A. (2022) · Pakistan Journal of Ophthalmology · doi:10.36351/pjo.v39i1.1452
Treatments for diabetic retinopathy and diabetic macular edema in pipeline
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00011-1
Introduction of Diabetic retinopathy and principles of treatment
Li, W., & Zhang, J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-93064-2.00007-x
Ashraf, M., Sun, J. K., Silva, P. S., Cavallerano, J. D., & Aiello, L. P. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_15
Ophthalmic Disease in Diabetes
Henriques, J., Vaz-Pereira, S., Nascimento, J., Dutra-Medeiros, M., Henriques, S., & Rosa, P. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_53
СОВРЕМЕННЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ МАКУЛЯРНОГО ОТЕКА У ПАЦИЕНТОВ С ДИАБЕТОМ
Янгиева, Н. Р., & Гиясова, А. О. (2023) · Advanced Ophthalmology · doi:10.57231/j.ao.2023.2.2.017
Toishubai, A., Davaatseren, U., Jamyanjav, B., Lim, S. T., Tuvaan, B., Tsengenbayar, M., Мунххишиг, Б., Luvsantseren, O., Jamyansuren, U., Munkhkhuyag, M., et al. (2016) · Central Asian Journal of Medical Sciences · doi:10.24079/cajms.2016.01.008
Treatment of diabetic macular edema: Bibliometric analysisPreprint
Wang, S., Shen, W., Wang, W., Xin, S., Ren, W., & Jin, K. (2024) · Research Square · doi:10.21203/rs.3.rs-3848475/v1
Progress in the Treatment of DME
Zou, X., Liu, Y., Cheng, S., & Zhang, Z. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.122007
Diabetic eye disease: novel therapeutic strategies
Vujosevic, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00007-5
Macular edema: A fearful complication of diabetic eye disease
Ghanem, G. O. B., & Fawzi, A. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00005-1
Elarabi, A. M. A., Eid, M. Z., & Samy, H. (2024) · Al-Azhar International Medical Journal /Al-Azhar International Medical Journal · doi:10.58675/2682-339x.2278
Laser Therapy to Treat Diabetic Macular Edema
Malviya, R., Meenakshi, D. U., & Goyal, P. (2024) · doi:10.1002/9781394237999.ch6
Bordon, A. F. (2024) · Springer eBooks · doi:10.1007/978-3-031-29358-0_24-1
Poh, S. S. J., Teo, K. Y. C., Goh, R. A., Lee, Q. X., Hamzah, H., Sim, S. S. C., Tan, C. S., Tan, N. C., Wong, T. Y., & Tan, G. S. W. (2025) · Eye · doi:10.1038/s41433-025-03725-1
Jennings, E., Chen, D. K., Geevarghese, A., Kaiser, A., Coulon, S. J., & Modi, Y. S. (2025) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20250127-02
Haritoglou, C., Iwersen, M., Müller, B., Beeke, E., Berk, H., Grüb, M., Lorenz, K., Scheffler, M., & Ziemssen, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093120
Saucedo, L., Pfister, I. B., Schild, C., & Garweg, J. G. (2025) · Ophthalmology Science · doi:10.1016/j.xops.2025.100838
Traitement de la rétinopathie diabétique
Massin, P., Dupas, B., Erginay, A., Feldman, S., & Lecleire-Collet, A. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78350-0.00008-8
Kumagai, K., Horie, E., Fukami, M., & Furukawa, M. (2025) · Cureus · doi:10.7759/cureus.95537
Medications for the Management of Retinopathy
Tran, E. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch26
ANTIBIOTIC PROPHYLAXIS FOR PREVENTING ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONS
Aleksander-Ivanov, Y., Cheidde, L., & Filho, L. A. Z. (2025) · Retina · doi:10.1097/iae.0000000000004743
Dupas, B., Castro‐Farías, D., Girmens, J., Eginay, A., Couturier, A., Villeroy, F., Delyfer, M., Creuzot-Garcher, C. P., Giocanti‐Auregan, A., Beral, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25670286
Dupas, B., Castro‐Farías, D., Girmens, J., Eginay, A., Couturier, A., Villeroy, F., Delyfer, M., Creuzot-Garcher, C. P., Giocanti‐Auregan, A., Beral, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25670169
Tunon-Robinson, I., Zhang, R., & Nguyen, A. K. (2026) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683251412321
Zhang, R., Tunon-Robinson, I., & Nguyen, A. K. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01371-8
Four-Year Outcomes of Faricimab in Diabetic Macular Edema in the RHONE-X Extension Trial: A Podcast
Sheth, V. S., & Vujosevic, S. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01470-6
Advances in Durable Anti-VEGF and Laser Therapy for Diabetic Macular Edema
赵, 泽. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693195
Beyond Anti-VEGF: Toward Integrated Precision Care in Diabetic Retinal Disease
González-Cortés, J. H., Gonzalez-Cantu, J. E., Bilgic, A., de Ribot, F. M., Sudhalkar, A. A., Kodjikian, L., Pelayes, D. E., Mathis, T., & Mohamed-Hamsho, J. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091178
Bordon, A. F. (2026) · Springer eBooks · doi:10.1007/978-3-032-23052-2_24
Metadata
- Authors
- Elman, M. J., Ayala, A., Bressler, N. M., Browning, D., Flaxel, C. J., Glassman, A. R., Jampol, L. M., & Stone, T. W.
- Affiliations
- Elman Retina Group (US)
- Jaeb Center for Health Research (US)
- Johns Hopkins University (US)
- Charlotte Eye Ear Nose & Throat Associates (US)
- Northwestern University (US)
- Retina Associates of Kentucky (US)
- Corresponding author
- Ayala, Allison
- ORCID
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 122
- Issue
- 2
- Pages
- 375-381
- ISSN
- 0161-6420 (ISSN-L)
- PMC
- PMC4520307
- OpenAlex
- W1980342089
- Cited by
- 562
- References
- 10
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 22 · 2023: 20 · 2022: 35 · 2021: 39 · 2020: 55 · 2019: 41 · 2018: 45 · 2017: 79 · 2016: 72 · 2015: 73
- FWCI
- 79.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Eye Institute (EY14231, EY-14229, EY18817, EY023207, U10EY018817, U10EY014229, U10EY023207, U10EY014231, UG1EY014231)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- diabetic macular edema, ranibizumab, intravitreal injection, best-corrected visual acuity, long-term visual outcomes, anti-VEGF therapy, vision loss, treatment duration extension, retinal laser treatment, anti-angiogenic therapy, treatment burden reduction
- MeSH terms
- Ranibizumab, Aged, Combined Modality Therapy, Diabetic Retinopathy, Female, Humans, Macular Edema, Male, Middle Aged, Visual Acuity, Treatment Outcome, Laser Coagulation, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
